17 alpha-hydroxylase deficiency prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Iqra Qamar (talk | contribs) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 6: | Line 6: | ||
[[Prenatal diagnosis]] of 17 alpha-hydroxylase deficiency is advised in order to prevent complications of the disease further in life. Prenatal administration of [[dexamethasone]], which is the drug of choice helps prevent complications. | [[Prenatal diagnosis]] of 17 alpha-hydroxylase deficiency is advised in order to prevent complications of the disease further in life. Prenatal administration of [[dexamethasone]], which is the drug of choice helps prevent complications. | ||
==Primary Prevention== | ==Primary Prevention== | ||
* [[Prenatal diagnosis]] of 17 alpha-hydroxylase deficiency is advised in order to prevent complications of the disease further in life. Prenatal administration of [[dexamethasone]], which is the drug of choice helps prevent complications. | * [[Prenatal diagnosis]] of 17 alpha-hydroxylase deficiency is advised in order to prevent complications of the disease further in life. | ||
* [[Prenatal]] administration of [[dexamethasone]], which is the drug of choice helps prevent complications. | |||
*Testing modalities include: | *Testing modalities include: | ||
**[[Amniotic fluid]] testing. | |||
**[[Oligonucleotides|Oligonucleotide]] [[hybridization]] of [[deoxyribonucleic acid]] ([[DNA]]) which is obtained from [[Chorionic villus sampling|chorionic villus biopsies]]. In this method, [[fetal]] [[DNA]] is extracted from maternal blood through noninvasive methods.<ref name="pmid27378492">{{cite journal |vauthors=Kazmi D, Bailey J, Yau M, Abu-Amer W, Kumar A, Low M, Yuen T |title=New developments in prenatal diagnosis of congenital adrenal hyperplasia |journal=J. Steroid Biochem. Mol. Biol. |volume=165 |issue=Pt A |pages=121–123 |year=2017 |pmid=27378492 |doi=10.1016/j.jsbmb.2016.06.016 |url=}}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Latest revision as of 12:52, 23 October 2017
|
17 alpha-hydroxylase deficiency Microchapters |
|
Differentiating 17 alpha-hydroxylase deficiency from other Diseases |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
17 alpha-hydroxylase deficiency prevention On the Web |
|
American Roentgen Ray Society Images of 17 alpha-hydroxylase deficiency prevention |
|
Risk calculators and risk factors for 17 alpha-hydroxylase deficiency prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Overview
Prenatal diagnosis of 17 alpha-hydroxylase deficiency is advised in order to prevent complications of the disease further in life. Prenatal administration of dexamethasone, which is the drug of choice helps prevent complications.
Primary Prevention
- Prenatal diagnosis of 17 alpha-hydroxylase deficiency is advised in order to prevent complications of the disease further in life.
- Prenatal administration of dexamethasone, which is the drug of choice helps prevent complications.
- Testing modalities include:
- Amniotic fluid testing.
- Oligonucleotide hybridization of deoxyribonucleic acid (DNA) which is obtained from chorionic villus biopsies. In this method, fetal DNA is extracted from maternal blood through noninvasive methods.[1]
References
- ↑ Kazmi D, Bailey J, Yau M, Abu-Amer W, Kumar A, Low M, Yuen T (2017). "New developments in prenatal diagnosis of congenital adrenal hyperplasia". J. Steroid Biochem. Mol. Biol. 165 (Pt A): 121–123. doi:10.1016/j.jsbmb.2016.06.016. PMID 27378492.